PACB
Closed
Pacific Biosciences Of California
1.29
+0.05 (+4.03%)
Last Update: 01 Jul 2025 23:08:00
Yesterday: 1.24
Day's Range: 1.2 - 1.31
Send
sign up or login to leave a comment!
When Written:
10.96
Pacific Biosciences of California (PacBio) is a biotechnology company that develops and manufactures DNA sequencing systems for scientific research and clinical diagnostics. The company was founded in 2004 and is headquartered in Menlo Park, California.
PacBio's technology is based on single-molecule, real-time (SMRT) sequencing, which allows for the direct observation of DNA synthesis in real-time. This method provides long read lengths and high accuracy, making it useful for applications such as genome assembly, structural variation detection, and epigenetics research.
PacBio's flagship product is the Sequel System, which was launched in 2016 and is capable of generating up to 10 times more data than the previous PacBio RS II system. The company also offers a range of consumables, software, and services to support its sequencing systems.
PacBio has collaborations with a number of academic and commercial partners, including Illumina, Roche, and Novogene. In addition, the company has received funding from various sources, including the National Institutes of Health and the Bill and Melinda Gates Foundation.
As of 2021, PacBio has a market capitalization of approximately $5 billion and employs over 600 people. The company is led by CEO Christian Henry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
PacBio's technology is based on single-molecule, real-time (SMRT) sequencing, which allows for the direct observation of DNA synthesis in real-time. This method provides long read lengths and high accuracy, making it useful for applications such as genome assembly, structural variation detection, and epigenetics research.
PacBio's flagship product is the Sequel System, which was launched in 2016 and is capable of generating up to 10 times more data than the previous PacBio RS II system. The company also offers a range of consumables, software, and services to support its sequencing systems.
PacBio has collaborations with a number of academic and commercial partners, including Illumina, Roche, and Novogene. In addition, the company has received funding from various sources, including the National Institutes of Health and the Bill and Melinda Gates Foundation.
As of 2021, PacBio has a market capitalization of approximately $5 billion and employs over 600 people. The company is led by CEO Christian Henry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!